“At Eyecare Medical Group in Portland, Maine, January represents the time we pay particular attention to getting the word out reminding patients to take advantage of the advances in the diagnosis and treatment of glaucoma as this sight stealing eye disease is a leading cause of preventable blindness,” commented Clement Berry, Chief Executive Officer of Eyecare Medical Group.
(PRWeb January 05, 2012)
The Retina Group of New York announced the availability of Eylea (aflibercept), the latest in a series of anti-VEGF medications for all patients with the wet (neovascular) form of macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older. The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. The studies showed that Eylea was as effective as Lucentis in maintaining most vision in 95% of patients and improved vision in over 30% of patients. The Food and Drug Administration approved Eylea on November 18, 2011 and it is now available to patients for treatment by the Retina Group of New York in their Hicksville and Hauppauge offices.
(PRWeb November 28, 2011)
The University of Illinois at Chicago’s Department of Ophthalmology and Visual Sciences today announced a multi-year financial pledge by St. Charles, Illinois-based Parent Petroleum Company, a partner with the non-profit organization, Hope for Vision. The funding will support the vision research into common blinding retinal conditions, such as diabetic retinopathy, age-related macular degeneration and retinitis pigmentosa.
(PRWeb November 17, 2011)
